Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Rheumatoid Arthritis

Table 4

Serum levels of bone turnover markers and bone metabolism proteins.

	Baseline	Follow-up	value
sRANKL (pmol/L)	0.32 [0.21–0.67]	0.18 [0.11–0.35]
OPG (pmol/L)	4.34 [2.60–5.82]	4.22 [3.05–5.08]	0.7990
sRANKL/OPG	0.08 [0.04–0.17]	0.05 [0.03–0.07]
DKK1 (pmol/L)	25.5 [18.1–43.3]	26.4 [21.9–31.7]	1.000
Sclerostin (pmol/L)	25.2 [16.94–33.8]	25.2 [19.2–29.3]	0.8577
CTX-I (ng/mL)	194.6 [176.6–430.7]	163.6 [152.1–173.9]
P1NP (ng/mL)	55.7 [46.3–61.3]	45.8 [39.6–48.9]
CTX/P1NP	3.36 [3.09–3.82]	3.71 [3.34–4.30]	0.5590

Enzyme-linked immunosorbent assay results are shown as median and interquartile range. sRANKL: soluble receptor activator of NF-κβ ligand; OPG: osteoprotegerin; DKK1: Dickkopf-related protein-1: CTX: carboxyterminal telopeptide of type I collagen; P1NP: total procollagen type 1 N-terminal propeptide; , , and . ^†Remained significant after correction for multiple comparisons.